<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02102477</url>
  </required_header>
  <id_info>
    <org_study_id>SPCG-15</org_study_id>
    <nct_id>NCT02102477</nct_id>
  </id_info>
  <brief_title>Surgery Versus Radiotherapy for Locally Advanced Prostate Cancer</brief_title>
  <acronym>SPCG-15</acronym>
  <official_title>Primary Radical Prostatectomy Versus Primary Radiotherapy for Locally Advanced Prostate Cancer: an Open Randomized Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Olof Akre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Karolinska University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective, open randomized phase III surgical trial seeks to study whether radical&#xD;
      prostatectomy (with or without the combination of external radiation) improves&#xD;
      prostate-cancer specific survival in comparison with primary radiation treatment and hormonal&#xD;
      treatment among patients diagnosed with locally advanced (T3) prostate cancer. Untreated or&#xD;
      conservatively treated locally advanced prostate cancer is associated with high mortality.&#xD;
      Modern curative treatment for advanced solid malign tumors include surgery and/or radiation&#xD;
      plus attempted chemotherapy if available to achieve both local control and elimination of&#xD;
      potential micro metastases. Whereas there is evidence that surgery can cure localized&#xD;
      prostate cancer, there are no clinical trials of multi-modal treatment of locally advanced&#xD;
      prostate cancer that includes surgical removal of the prostate.&#xD;
&#xD;
      One potential advantage of adding prostatectomy to the treatment of LAPC is that removing the&#xD;
      prostate enables a full pathological assessment of the tumor characteristics and thus a&#xD;
      better estimation of the risk of recurrence. Surgical treatment could thus reduce the numbers&#xD;
      needed to treat with chemotherapy and radiation, and thus improve quality of life after&#xD;
      treatment. In addition, evidence indicate that residual cancer in the prostate occurs in 25%&#xD;
      after radiation treatment (56) and surgical removal of the prostate may improve survival&#xD;
      beyond what can be achieved by radiation and ADT. On the other hand, patients treated with&#xD;
      surgery, radiation and hormones will experience side effects of all three treatment&#xD;
      modalities and might fare better if radiotherapy plus hormones can provide oncological&#xD;
      control without prior surgery.&#xD;
&#xD;
      A randomized clinical trial comparing two multimodal treatment regimens of which one includes&#xD;
      a radical prostatectomy is therefore warranted.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 2014</start_date>
  <completion_date type="Anticipated">December 2031</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cause specific survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Cause-specific survival (CSS) will be calculated as &quot;1-cause specific mortality. Mortality and mortality causes will be ascertained from the nationwide Cause-of-Death Register. In the absence of a functioning Cause-of-Death register, an endpoint committee of at least 2 medical doctors will determine the cause of death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Metastasis free survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Composite endpoint of time to metastasis and survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life - general psychological, urinary, bowel and sexual health</measure>
    <time_frame>At 1,2,5 and 10 years after randomization</time_frame>
    <description>Questionnaire-based evaluation of general psychological health, urinary health, bowel health, and sexual health.&#xD;
Questions about self Questions about quality of life in the past month (scale 1 to 7; 1=no quality, 7=the best quality) Depression and anxiety (scale 1 to 7; 1=no, 7=very) Symptom Form (EPIC-26) (scale 1 to 5; 1= no problem, 5=major problem) Questions about the urinary tract Questions about sexual function Questions about bowel function Questions about prostate cancer - diagnosis and treatment Questions about prostate cancer check-ups Questions about hormone/castration therapy and its significance Questions about pain and lymph swelling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Overall survival (OS) will be calculated as &quot;1-overall mortality. Mortality data will be ascertained through the nationwide Cause-of-Death Register.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to castration-resistant prostate cancer</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Ascertained at follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical progression</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Ascertained at follow-up visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Ascertained at visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular disease</measure>
    <time_frame>Up to 10 years</time_frame>
    <description>Data from national PcBaSe-register (https://snd.gu.se/en/catalogue/study/ext0014), a registry where the national prostate cancer registry (NPCR, www.npcr.se) has been linked to the Swedish National Cancer Register, the Cause of Death Register, the Prescribed Drug Register, the National Patient Register, and the Acute Myocardial Infarction Register, the Register of the Total Population, the Longitudinal Integration database for health insurance and labour market studies (LISA), the Multi-Generatioon Register and several other population-based registers.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Health-care consumption</measure>
    <time_frame>Annually up to 10 years</time_frame>
    <description>Annual Defined Daily Dose (DDD) of analgesics, prescription databases</description>
  </other_outcome>
  <other_outcome>
    <measure>Health-care consumption</measure>
    <time_frame>Annually up to 10 years</time_frame>
    <description>Annual number of days of hospitalization from patient registers</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1200</enrollment>
  <condition>Prostatic Neoplasms</condition>
  <arm_group>
    <arm_group_label>Prostatectomy/Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with locally advanced prostate adenocarcinoma recieves Prostatectomy/Surgery with or without adjuvant or salvage radiotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiotherapy with adjuvant androgen deprivation therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with locally advanced prostate adenocarcinoma treated with adjuvant androgen deprivation therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Prostatectomy/Surgery</intervention_name>
    <description>Radical prostatectomy with or without adjuvant or salvage radiotherapy</description>
    <arm_group_label>Prostatectomy/Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radiotherapy with adjuvant androgen deprivation therapy</intervention_name>
    <description>Radiotherapy with adjuvant androgen deprivation therapy</description>
    <arm_group_label>Radiotherapy with adjuvant androgen deprivation therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¤75, at the time of randomization&#xD;
&#xD;
          -  Diagnosed histopathologically confirmed and untreated prostatic adenocarcinoma&#xD;
&#xD;
          -  The general condition and mental status of patients shall permit observation in&#xD;
             accordance with the study protocol&#xD;
&#xD;
          -  Tumor stage (T, M, N):&#xD;
&#xD;
        T3 stage (as indicated by digital rectal examination or MR imaging or other validated&#xD;
        imaging technique) T4 tumors can be included if considered resectable/treatable on MR&#xD;
        imaging Significant extra-capsular tumor extension in biopsy (rare but acceptable for&#xD;
        inclusion) M0 (no sign of distant metastases) confirmed by bone scan or CT or MRT of axial&#xD;
        skeleton (at a maximum of pelvis and lumbar vertebral column) N0 stage, defined in&#xD;
        accordance to the RECIST guidelines as no sign of macroscopic retroperitoneal lymph-node&#xD;
        metastases &gt;=1.5 cm (short axis) on CT scan, PET-CT, or MRT or more than one suspected&#xD;
        lymph-node metastases Presence Gleason grade pattern 4 or 5&#xD;
&#xD;
        - Signed Informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with a PSA value of &gt; 100 ng/mL&#xD;
&#xD;
          -  Any medical condition that, in the opinion of the investigator, might interfere with&#xD;
             the evaluation of the study objectives Patients with contraindications for either&#xD;
             prostatectomy or radiotherapy to the prostate are not eligible for the study. Most&#xD;
             contraindications for these treatments are relative, but in general, radiotherapy may&#xD;
             be precluded among patients with:&#xD;
&#xD;
          -  Anorectal disease, such as fistulae, CrohnÂ´s disease, and ulcerative colitis&#xD;
&#xD;
          -  Significant obstructive lower urinary tract symptoms&#xD;
&#xD;
          -  Proximal stricture of the urethrae&#xD;
&#xD;
          -  Severe neurogenic bladder dysfunction&#xD;
&#xD;
          -  Enlarged prostate beyond 70-90 ml&#xD;
&#xD;
          -  Previous radiotherapy to the pelvic region&#xD;
&#xD;
        On the other hand, surgery may be precluded among patients with:&#xD;
&#xD;
          -  Massive local tumor progression, particularly in the apical region&#xD;
&#xD;
          -  Massive abdominal obesity&#xD;
&#xD;
          -  Contraindications to anesthesia&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Johan Stranne, M.D ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sahlgrenska University Hospital, Department of Urology, SE- 413 45 Gothenburg</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Camilla Thellenberg Karlsson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UmeÃ¥ University Hospital, Department of Radiation Science, SE-901 87 UmeÃ¥ Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Eva M Johansson, R.N PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, NobelsvÃ¤g, SE- 171 77 Solna, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Gunnar Steineck, M.D Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska Institute, NobelsvÃ¤g, SE-171 77 Solna, Sweden</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Klaus Brasso, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, department Urology, DK-2001-Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter M Meidahl Petersen, M.D ass prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rigshospitalet, Region h, Department of Oncology, Blegdamsvej 9, DK- 2001, Copenhagen, Denmark</affiliation>
  </overall_official>
  <overall_official>
    <last_name>BjÃ¸rn Brennhovd, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Urology, P.O Box 4950 Nydalen, N-0424, Oslo Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Wolfgang Lilleby, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Oslo University Hospital, Department of Radiation Therapy, P.O Box 4950, N-0424, Nydalen Oslo, Norway</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Antti Rannikko, M.D ass.prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,StenbÃ¤ckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mauri Kouri, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,StenbÃ¤ckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Tuomas Mirtti, M.D PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Helsinki University Central Hospital, Department Urology,StenbÃ¤ckinkatu 9, FIN-00290 Helsinki , Finland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Olof Akre, Prof.</last_name>
    <phone>+46-8-517 700 00</phone>
    <email>olof.akre@ki.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Aalborg University Hospital</name>
      <address>
        <city>Aalborg</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Niels Harving, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Niels Harving, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mette Moe Kempel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lise Bentzen, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Lise Bentzen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martin Mortensen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshospitalet, Region h, Department Oncology</name>
      <address>
        <city>Copenhagen</city>
        <zip>DK-2001</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter M Meidahl Petersen, M.D ass</last_name>
    </contact>
    <investigator>
      <last_name>Peter M Meidahl Petersen, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rigshopsitalet Department urology</name>
      <address>
        <city>Copenhagen</city>
        <zip>SE- 2001</zip>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Klaus Brasso, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Klaus Brasso, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herlev Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Henrik Jacobsen, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Henrik Jacobsen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Henriette Lindberg, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SteinbjÃ¸rn Hansen, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>SteinbjÃ¸rn Hansen, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mads Hvid, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Lund, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsinki University Hospital, Department of Urology</name>
      <address>
        <city>Helsinki</city>
        <zip>FIN-00290</zip>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antti Rannikko, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Antti Rannikko, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mauri Kouri, M.D PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tuomas Mirtti, M.D PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampere University Hospital, Pihlajalinna Koskiklinikka</name>
      <address>
        <city>Tampere</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Teuvo Tammela, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Teuvo Tammela, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Teemu Murtola, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Petri Reinikainen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turku University Hospital</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter BostrÃ¶m, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Peter BostrÃ¶m, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kari Syvanen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Paula Lindholm, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SÃ¸rlandet Hospital</name>
      <address>
        <city>Kristiansand</city>
        <zip>4604</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph MÃ¼ller, Ph.D. M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Christoph MÃ¼ller, Ph.D. M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carl Hammarlund, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Department of radiation Therapy</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Lilleby, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Wolfang Lilleby, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oslo University Hospital, Department Urology</name>
      <address>
        <city>Oslo</city>
        <zip>N-0424</zip>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bjorn Brennhovd, M.D ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Bjorn Brennvold, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital of North Norway</name>
      <address>
        <city>TromsÃ¸</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hege Sagstuen, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Hege Sagstuen, Ph.D. M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tore Knutsen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>BÃ¥rd Soltun, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kari Margrethe Larsen, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Olavs Hospital</name>
      <address>
        <city>Trondheim</city>
        <country>Norway</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Torgrim Tandstad, Ph.D.</last_name>
    </contact>
    <investigator>
      <last_name>Torgrim Tandstad, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Heidi Knobel, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Kristin Toftaker Killingberg, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arne Solberg, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Falu Lasarett</name>
      <address>
        <city>Falun</city>
        <zip>SE 791 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hampus Nugin, MD</last_name>
    </contact>
    <investigator>
      <last_name>Hampus Nugin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska University Hospital</name>
      <address>
        <city>GÃ¶teborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Stranne, ass prof</last_name>
    </contact>
    <investigator>
      <last_name>Johan Stranne, M.D ass prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Helsingborgs Lasarett</name>
      <address>
        <city>Helsingborg</city>
        <zip>SE 25187</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Konstantinos Lentaris, MD</last_name>
    </contact>
    <investigator>
      <last_name>Konstantinos Lentaris, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LÃ¤nssjukhuset Ryhov</name>
      <address>
        <city>JÃ¶nkÃ¶ping</city>
        <zip>SE 553 05</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Jonsson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anders Jonsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kirurgkliniken, Blekingesjukhuset</name>
      <address>
        <city>Karlskrona</city>
        <zip>371 41</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Mousa Kadhem, M.D.</last_name>
      <phone>+46 455 73 10 00</phone>
    </contact>
    <investigator>
      <last_name>Amer Mousa Kadhem, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>LinkÃ¶ping University Hospital</name>
      <address>
        <city>LinkÃ¶ping</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Per Skoglund, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Per Skoglund, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>MÃ¥ns Agrup, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>SkÃ¥ne University Hospital</name>
      <address>
        <city>MalmÃ¶</city>
        <zip>SE 205 02</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anders Bjartell, MD</last_name>
    </contact>
    <investigator>
      <last_name>Anders Bjartell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vrinevis Hospital</name>
      <address>
        <city>NorrkÃ¶ping</city>
        <zip>SE 601 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>SE 171 76</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olof Akre, Prof</last_name>
    </contact>
    <investigator>
      <last_name>Mats Olsson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Capio St GÃ¶ran Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lillemor Nygren, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Lillemor Nygren, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie Hjelm-Eriksson, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sundvalls Hospital</name>
      <address>
        <city>Sundsvall</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Styrke, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Johan Styrke, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lars Beckman, M.D.</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UmeÃ¥ University Hospital</name>
      <address>
        <city>UmeÃ¥</city>
        <zip>SE 901 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camilla Thellenberg, M.D PhD</last_name>
    </contact>
    <investigator>
      <last_name>Camilla Thellenberg, M.D PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uppsala Akademiska Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>SE 751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Johanssson, M.D</last_name>
    </contact>
    <investigator>
      <last_name>Eva Johanssson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet</name>
      <address>
        <city>VÃ¤xjÃ¶</city>
        <zip>SE 352 34</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Elwaheidy, MD</last_name>
    </contact>
    <investigator>
      <last_name>Amer Elwaheidy, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centrallasarettet VÃ¤xjÃ¶ Hospital</name>
      <address>
        <city>VÃ¤xjÃ¶</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amer Elwaheidy, M.D.</last_name>
    </contact>
    <investigator>
      <last_name>Amer Elwaheidy, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ã–stersund Hospital</name>
      <address>
        <city>Ã–stersund</city>
        <zip>SE 831 31</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Lundgren, MD</last_name>
    </contact>
    <investigator>
      <last_name>Andreas Lundgren, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Finland</country>
    <country>Norway</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>March 31, 2014</study_first_submitted>
  <study_first_submitted_qc>March 31, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2014</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Karolinska University Hospital</investigator_affiliation>
    <investigator_full_name>Olof Akre</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Prostatic neoplasms</keyword>
  <keyword>Locally advanced</keyword>
  <keyword>Radiotherapy</keyword>
  <keyword>Surgery</keyword>
  <keyword>Mortality</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Androgens</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

